Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Telix Pharma Enters into Licensing Agreement with Wilex 12
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Heidelberg Pharma Enters into Agreement with Celonic 15
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 16
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 17
Licensing Agreements 18
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 18
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 19
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 20
Heidelberg Pharma Enters Into Licensing Agreement With Roche For Antibody Targeted Amanitin Conjugates 21
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX 22
Equity Offering 23
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 23
Wilex Raises USD5.4 Million in Rights Offering of Shares 24
Wilex to Raise USD4.7 Million in Rights Offering of Shares 25
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Debt Offering 33
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
Asset Transactions 34
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
Acquisition 35
WILEX Acquires Heidelberg Pharma For US$26.8 Million 35
Heidelberg Pharma AG – Key Competitors 37
Heidelberg Pharma AG – Key Employees 38
Heidelberg Pharma AG – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Jul 13, 2017: WILEX reports on first half-year 40
Apr 12, 2017: WILEX: Interim management statement on the first three months of 2017 42
Mar 30, 2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business 44
Jul 14, 2016: WILEX publishes Half-yearly Financial Report 46
Apr 14, 2016: WILEX AG: Interim management statement on the first quarter of 2016 48
Mar 22, 2016: WILEX announces financial figures for the 2015 financial year and reports on course of business 51
Corporate Communications 53
Jun 02, 2016: WILEX announces change on the Executive Management Board 53
Apr 06, 2016: WILEX plans change on the Supervisory Board 54
Product News 55
03/01/2016: RedHill Biopharma Provides Update on MESUPRON 55
Product Approvals 56
Jan 13, 2016: WILEX’s partner Link Health submits IND application for clinical Phase I with the uPA inhibitor MESUPRON in China 56
Other Significant Developments 57
Oct 13, 2016: WILEX: Interim Management Statement on the First Nine Months of 2016 57
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heidelberg Pharma AG, Deals By Therapy Area, 2011 to YTD 2017 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Telix Pharma Enters into Licensing Agreement with Wilex 12
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Heidelberg Pharma Enters into Agreement with Celonic 15
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 16
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 17
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 18
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 19
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 20
Heidelberg Pharma Enters Into Licensing Agreement With Roche For Antibody Targeted Amanitin Conjugates 21
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX 22
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 23
Wilex Raises USD5.4 Million in Rights Offering of Shares 24
Wilex to Raise USD4.7 Million in Rights Offering of Shares 25
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
WILEX Acquires Heidelberg Pharma For US$26.8 Million 35
Heidelberg Pharma AG, Key Competitors 37
Heidelberg Pharma AG, Key Employees 38
Heidelberg Pharma AG, Subsidiaries 39